Evidence map›Paper›PMID 42258060›Full record

ArticleFamilial cancer2026

Characterization of the molecular and clinical features of Multilocus Inherited Neoplasia Allelic Syndrome (MINAS) cases in the Turkish population.

Mehmet Berkay Akcan, Ali Duru, Kadri Murat Erdoğan, Özge Özer Kaya, Selcan Keşan, Özgür Kırbıyık, Tuba Sözen Türk, Feyza Altunbaş Yalabık, Yaşar Bekir Kutbay, Özlem Anlaş and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mehmet Berkay AkcanGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey. dr.mberkayakcan@gmail.com.ORCID 0000-0003-0160-0377
Ali DuruGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0009-0007-8378-4806
Kadri Murat ErdoğanGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0003-0097-1424
Özge Özer KayaGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0001-6731-2461
Selcan KeşanGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0002-6762-9634
Özgür KırbıyıkGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0003-1333-2007
Tuba Sözen TürkGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0001-8371-2764
Feyza Altunbaş YalabıkGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0009-0002-1181-829X
Yaşar Bekir KutbayGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0002-9006-5072
Özlem AnlaşGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0002-2861-1693
Merve Saka GüvençGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0001-8842-0381
Altuğ KoçGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0002-8366-6806
Olçun Ümit ÜnalMedical Oncology Department, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0001-7698-3574
Berk ÖzyılmazGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0002-7784-8136
Taha Reşid ÖzdemirGenetic Disease Diagnosis and Evaluation Center, İzmir City Hospital, İzmir, Turkey.ORCID 0000-0003-4870-6945

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multilocus Inherited Neoplasia Allelic Syndrome (MINAS) is a rare genetic syndrome characterized by the presence of multiple pathogenic/likely pathogenic(P/LP) variants in different cancer predisposition genes within the same individual. Patients with MINAS may face early age at onset and multiple primary malignancies. In our study, we aimed to characterize the prevalence and clinical landscape of MINAS in a major Turkish hereditary cancer cohort. We retrospectively analyzed NGS oncorisk panel results of 5000 individuals who presented to the Medical Genetics Unit of İzmir City Hospital between 2024 and 2025 with a preliminary diagnosis of hereditary cancer syndrome due to a personal and/or family history of malignancy. Our diagnostic workflow uniquely integrated Single Nucleotide Variant (SNV) detection with Copy Number Variation (CNV) calling. MINAS prevalence was 0.86% (43/5000). Dual-gene alterations were detected in 42 patients, while one featured a triple-gene alteration (BRIP1-CHEK2-MUTYH). The most frequent combination was BRCA2-CHEK2 (n = 6). Notably, CNVs were identified in 7% of cases, highlighting the necessity of structural variant analysis. Malignancy was present in 70% (30/43) of carriers, with a median age at first diagnosis of 47 years (range: 31-77). Early-onset cancer (< 40 years) was observed in 32% of cases. Our findings represents the largest Turkish MINAS cohort to date. While phenotypes often align with the most penetrant allele, spesific instances may hint at the potential for synergistic effects in certain individuals. Management should transition toward personalized, multi-variant surveillance strategies incorporating both SNV and CNV data.

Indexed as

Neoplastic Syndromes, HereditaryAdultAgedAge of OnsetDNA Copy Number VariationsFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPrevalenceRetrospective StudiesTurkeyCancerHereditaryMINASNGS

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.